Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA)) received US Food and Drug Administration (FDA) approval to market its generic version of anti-seizure drug Topamax.
Teva has already begun shipping the drug.
Based on IMS sales data, annual US sales of Topamax reached about $2.4 billion in 2008.
Teva will market its version of the Topiramate tablets, the medicine in Topamax, in dosages of 25, 50, 100, and 200 mg.
Topamax is made by Johnson and Johnson unit Ortho-McNeil.
Shares in Teva closed on Friday at $45.16, giving it a market cap of $40.13 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on March 29, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009